注射用卡瑞利珠单抗致自身免疫性溶血性贫血1例分析

doi:10.19803/j.1672-8629.20250180

中国药物警戒 ›› 2026, Vol. 23 ›› Issue (6): 696-698.
DOI: 10.19803/j.1672-8629.20250180

注射用卡瑞利珠单抗致自身免疫性溶血性贫血1例分析

兰芝荟¹, 卜丽佳², 宁洁^2,*, 江洁美³, 杨彦彪¹

¹兰州市第一人民医院药剂科,甘肃兰州 730000;
²安徽医科大学第一附属医院肿瘤内科,安徽合肥 230022;
³安徽医科大学第一附属医院药剂科,安徽合肥 230022

收稿日期:2025-03-27 出版日期:2026-06-15 发布日期:2026-06-18
通讯作者: ^*宁洁,女,博士,主任医师,临床肿瘤学。E-mail: nj830921@126.com
作者简介:兰芝荟,女,硕士,主管药师,肿瘤临床药学。

One Case of Autoimmune Hemolytic Anemia Caused by Camrelizumab for Injection

LAN Zhihui¹, BU Lijia², NING Jie^2,*, JIANG Jiemei³, YANG Yanbiao¹

¹Department of Pharmacy, the First People’s Hospital of Lanzhou, Gansu Lanzhou 730000, China;
²Department of Oncology, the First Affiliated Hospital of Anhui Medical University, Hefei Anhui 230022, China;
³Department of Pharmacy, the First Affiliated Hospital of Anhui Medical University, Hefei Anhui 230022, China

Received:2025-03-27 Online:2026-06-15 Published:2026-06-18

摘要/Abstract

摘要： 目的探讨注射用卡瑞利珠单抗致自身免疫性溶血性贫血（AIHA）的不良反应,为临床安全用药提供参考。方法对1例腮腺癌患者使用免疫检查点抑制剂（ICI）后出现严重贫血的病例进行分析及文献回顾。结果根据患者病史、实验室检查及用药时间关联性,注射用卡瑞利珠单抗致AIHA为“很可能”,经过输血、大剂量激素及免疫球蛋白治疗后,患者贫血逐渐好转。结论 ICI引起的AIHA十分罕见,且早期很难发现,经发现即为严重贫血。因此,临床使用ICI时应加强对免疫相关不良反应监测和识别,特别是长期使用的患者。

关键词: 卡瑞利珠单抗, 贫血, 自身免疫性溶血性贫血, 药品不良反应, 腮腺癌

Abstract: Objective To explore such adverse reactions as autoimmune hemolytic anemia (AIHA) caused by camrelizumab for injection in order to provide a reference for safe medications. Methods One case of severe anemia following the use of an immune checkpoint inhibitor (ICI) in a patient with parotid gland carcinoma was analyzed based on related literature. Results Based on the patient’s medical history, results of laboratory tests, and the timing of drug administration, the patient’s AIHA was considered an adverse reaction caused by camrelizumab for injection. Conclusion AIHA caused by ICI is very rare because it is difficult to detect at an early stage. Once detected, anemia is usually severe. Therefore, immune related adverse reactions should be monitored and identified when ICI is used clinically, especially among chronic users.

Key words: Camrelizumab, Hemolysis, Autoimmunity Hemolytic Anemia, Adverse Drug Reaction, Parotid Gland Carcinoma

中图分类号:

兰芝荟, 卜丽佳, 宁洁, 江洁美, 杨彦彪. 注射用卡瑞利珠单抗致自身免疫性溶血性贫血1例分析[J]. 中国药物警戒, 2026, 23(6): 696-698.

LAN Zhihui, BU Lijia, NING Jie, JIANG Jiemei, YANG Yanbiao. One Case of Autoimmune Hemolytic Anemia Caused by Camrelizumab for Injection[J]. Chinese Journal of Pharmacovigilance, 2026, 23(6): 696-698.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20250180

https://zgywjj.magtechjournal.com/CN/Y2026/V23/I6/696

参考文献

[1] DELANOY N, MICHOT JM, COMONT T, et al.Haematological Immune-Related Adverse Events Induced by Anti-PD-1 or Anti-PD-L1 Immunotherapy: a Descriptive Observational Study[J]. Lancet Haematology, 2019, 6(1): 48-57.
[2] JOHNSON DB, NEBHAN CA, MOSLEHI JJ, et al.Immune-Checkpoint Inhibitors: Long-Term Implications of Toxicity[J]. Nature Reviews Clinical Oncology, 2022, 19: 254-267.
[3] BARCELLINI W, FATTIZZO B.The Changing Landscape of Autoimmune Hemolytic Anemia[J]. Frontiers in Immunology, 2020, 11: 946.
[4] SALIBA AN, XIE Z, HIGGINS AS, et al.Immune-Related Hematologic Adverse Events in the Context of Immune Checkpoint Inhibitor Therapy[J]. American Journal of Hematology, 2021, 96(10): 362-367.
[5] TANIOS GE, DOLEY PB, MUNKER R.Autoimmune Hemolytic Anemia Associated with the Use of Immune Checkpoint Inhibitors for Cancer: 68 Cases from the Food and Drug Administration database and Review[J]. European Journal of Haematology, 2019, 102(2): 157-162.
[6] LEAF RK, FERRERI C, RANGACHARI D, et al.Clinical and Laboratory Features of Auto Immune Hemolytic Anemia Associated with Immune Checkpoint Inhibitors[J]. American Journal of Hematology, 2019, 94(5): 563-574.
[7] KRAMER R, ZAREMBA A, MOREIRA A, et al.Hematological Immune Related Adverse Events after Treatment with Immune Checkpoint Inhibitors[J]. European Journal of Cancer, 2021, 147: 170-181.
[8] UQBA K, FARMAN A, MUHAMMAD SK, et al.Immunotherapy-Associated Autoimmune Hemolytic Anemia[J]. Journal for Immunotherapy of Cancer, 2017, 5: 1-4.
[9] TANJA F, SIMON F, MAYA B, et al.Severe Autoimmune Hemolytic Anemia Following Immunotherapy with Checkpoint Inhibitors in Two Patients with Metastatic Melanoma: a Case Report[J]. Frontiers in Immunology, 2024, 15: 1-9.
[10] MICKAËL M, HOAN-MY N, CLÉMENT B, et al. Immune Checkpoint Inhibitor-Related Cytopenias: about 68 Cases from the French Pharmacovigilance Database[J]. Cancers, 2022, 14(5030): 1-10.
[11] LI CL, SHU JH, LI XG, et al.Excavation and Evaluation of Adverse Reaction Signals of 4 Kinds of Imported PD-1/PD-L1 Inhibitors[J]. China Pharmacy(中国药房), 2022, 33(7): 873-878.
[12] YU X, ZHOU Y, LI Q, et al.Retrospective Analysis of the Literature on Adverse Reactions of 4 Domestic PD-1[J]. Chinese Journal of Clinical Pharmacology and Therapeutics(中国临床药理学与治疗学), 2024, 29(8): 887-898.
[13] KOUSEI NK, KAZUYA T, MINORI H, et al.Acute Myeloid Leukemia and Myelodysplastic Syndrome Associated with a Combination of Immune Checkpoint Inhibitor and Platinum-Based Chemotherapy[J]. Thoracic Cancer, 2023, 14: 2225-2228.
[14] BAKACS T, MOSS RW, KLEEF R, et al.Exploiting Autoimmunity Unleashed by Low-Dose Immune Checkpoint Blockade to Treat Advanced Cancer[J]. Scandinavian Journal of Immunology, 2019, 90(6): 1-11.
[15] JÄGER U, BARCELLINI W, BROOME CM, et al. Diagnosis and Treatment of Autoimmune Hemolytic Anemia in Adults: Recommen-dations from the First International Consensus Meeting[J]. Blood Reviews, 2020, 41: 100648.
[16] OGAWA K, ITO J, FUJIMOTO D, et al.Exacerbation of Autoimmune Hemolytic Anemia Induced by the First Dose of Programmed Death-1 Inhibitor Pembrolizumab: a Case Report[J]. Invest New Drugs, 2018, 36(3): 509-512.
[17] YANG ZJ, NING XL, LIU ZM, et al.Severe Anemia Associated with Immune Checkpoint Inhibitor: a Case Report[J]. International Journal of Gynecology(国际妇产科学杂志), 2024, 51(4): 438-441.
[18] Red Blood Cell Disease (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association. Guidelines for the Diagnosis and Treatment of Autoimmune Hemolytic Anemia in Chinese Adults[J]. Chin J Hematol(中华血液学杂志), 2023, 44(1): 12-18.
[19] VILLA-CRESPO L, PODLIPNIK S, ANGLADA N, et al.Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival[J]. Cancers (Basel), 2022, 14(5): 1-11.
[20] KROLL MH, ROJAS-HERNANDEZ C, YEE C.Hematologic Complications of Immune Checkpoint Inhibitors[J]. Blood, 2022, 139: 3594-3604.

注射用卡瑞利珠单抗致自身免疫性溶血性贫血1例分析

One Case of Autoimmune Hemolytic Anemia Caused by Camrelizumab for Injection

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	王春婷, 张瑞芳, 邓彬, 邹箴蕾, 王琨. 右旋糖酐铁注射液不良反应探析[J]. 中国药物警戒, 2026, 23(6): 672-676.
[2]	潘艳娟, 岳珂欣, 刘伟杰, 王领军, 王传升. 243例奥氮平不良反应报告分析[J]. 中国药物警戒, 2026, 23(6): 677-680.
[3]	王雨婷, 吕欣鸽, 潘晨, 武一, 崔向丽. 免疫检查点抑制剂致相关肠炎不良反应报告分析[J]. 中国药物警戒, 2026, 23(6): 681-685.
[4]	文冉苗, 陈悦, 杨彩华. 围产期盐酸克林霉素注射液致急性泛发性发疹性脓疱病2例分析[J]. 中国药物警戒, 2026, 23(6): 686-689.
[5]	李化龙, 王凌峰, 卢倩. 达格列净片致阴囊炎伴局部坏死1例分析[J]. 中国药物警戒, 2026, 23(6): 690-692.
[6]	王浩, 潘澎, 秦海军, 王建平. 肤痔清软膏致下肢水肿1例分析[J]. 中国药物警戒, 2026, 23(6): 699-701.
[7]	刘影, 薛红委, 庞楠, 杨中一, 柯文缘, 刘玲. 445例贝伐珠单抗注射液严重不良反应报告分析[J]. 中国药物警戒, 2026, 23(5): 547-552.
[8]	杜妍, 杨春兰, 孙旭群, 方玲. 121例PD-1/PD-L1抑制剂不良反应报告分析[J]. 中国药物警戒, 2026, 23(5): 553-557.
[9]	李兴桥, 马思佳. 基于真实世界数据的他汀类药品不良反应信号分析[J]. 中国药物警戒, 2026, 23(5): 558-563.
[10]	魏伟, 权勤波, 王玲华, 田月洁, 黄琳, 李娜, 王维波. 以某中药制剂为实证的真实世界药品不良反应可视化研究[J]. 中国药物警戒, 2026, 23(5): 564-568.
[11]	邹蕊, 吴雨桐, 周玥, 李琴, 孟召友. 特瑞普利单抗注射液致免疫检查点抑制剂相关重症肌无力合并急性心肌炎1例分析[J]. 中国药物警戒, 2026, 23(5): 569-571.
[12]	汤柳, 李洋, 罗广文, 鲍引娣. 利奈唑胺注射液致药物性肝损伤1例分析[J]. 中国药物警戒, 2026, 23(5): 572-574.
[13]	戴彪, 张松, 邓逸芸, 曹银, 张元元, 李培培, 梁俊. 硫普罗宁肠溶胶囊致粒细胞缺乏症1例分析[J]. 中国药物警戒, 2026, 23(5): 575-577.
[14]	王阿明, 魏筱, 吴慧, 张琳琳, 杨莉. 普瑞巴林胶囊致急性肝损伤1例分析[J]. 中国药物警戒, 2026, 23(5): 578-580.
[15]	张琴, 郑晓媛. 度普利尤单抗注射液致关节疼痛与肌无力1例分析[J]. 中国药物警戒, 2026, 23(5): 581-584.